Endocrine inactive and gonadotroph adenomas: Diagnosis and management

Journal of Neuro-Oncology

Volumn 54, Issue 2, 2001, Pages 167-177

  Losa, M ^a   Mortini, P ^a   Barzaghi, R ^a   Franzin, A ^a   Giovanelli, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Gonadotropins; Pituitary neoplasm; Pituitary surgery; Radiotherapy

Indexed keywords

ANISAMIDE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; IODINE 123; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER INVASION; COMPRESSION; CRANIOPHARYNGIOMA; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; ENDOCRINE SURGERY; HEADACHE; HEALTH CARE MANAGEMENT; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; IMMUNOCYTOCHEMISTRY; MASS; MENINGIOMA; NEURORADIOLOGY; OPTIC CHIASM; POSITRON EMISSION TOMOGRAPHY; RADIATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGICAL TECHNIQUE; SYMPTOM; TUMOR RECURRENCE; VISUAL IMPAIRMENT;

ADENOMA; DIAGNOSIS, DIFFERENTIAL; HUMANS; PITUITARY HORMONES; PITUITARY NEOPLASMS;

EID: 0035183048     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012965617685     Document Type: Review

References (84)

1. Gonadotroph cell adenomas of the pituitary
2. Hormone production in clinically nonfunctioning pituitary adenomas
3. LH and FSH secretion and responses to GnRH and TRH in patients with clinically functionless pituitary adenomas
4. Epidemiology of pituitary tumors
5. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas
6. The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas
7. Nonsecreting pituitary tumors
8. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine
9. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation
10. A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma
11. Ovarian hyperstimulation caused by a gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman
12. Hypersecretion of LH and FSH by a pituitary adenoma
13. Testicular enlargement and elevated serum inhibin concentrations occur in patients with pituitary macroadenomas secreting FSH
14. Sexual precocity in a boy due to hypersecretion of LH and prolactin by a pituitary adenoma
15. Precocious puberty in a boy with a PRL-LH and FSH secreting pituitary tumor: Hormonal and immunocytochemical studies
16. Immunodetection of chorionic gonadotropin and its subunits in human nonfunctioning pituitary adenomas
17. Prevalence of alpha-subunit hypersecretion in patients with pituitary tumors: Clinically non-functioning and somatotroph adenomas
18. Serum levels of β-subunit of chorionic gonadotropin in patients with pituitary tumors
19. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: Relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone and bromocriptine
20. Recognition of gonadotroph adenomas in women
21. Imbalanced follicle-stimulating hormone beta-subunit hormone biosynthesis in human pituitary adenomas
22. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone β subunit response to thyrotropin-releasing hormone
23. Responsiveness of gonadotropins to TRH in patients with nonfunctioning pituitary adenomas: Correlation with immunohistochemical results. Highlights in Molecular and Clinical Endocrinology
24. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro
25. Pulsatile glycoprotein hormone secretion in glycoprotein-producing pituitary tumors
26. New technique for quantitation of pituitary adenoma size: Use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist
27. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors
28. Current tools in the diagnosis of pituitary tumors
29. Imaging of pituitary tumours
30. 3]-octreotide: The Rotterdam experience in more than 1000 patients
31. 123I]SDZ 204-090)
32. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
33. Differentiation of pituitary adenoma and meningioma: Visualization with positron emission tomography and [11C]-L-deprenyl
34. Demonstration of specific dopamine receptors on human pituitary adenomas
35. 18F]fluoro-ethyl-spiperone
36. Recurrence of chromophobe pituitary adenomas after operation and post-operative radiotherapy
37. Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas
38. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy
39. The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary tumours
40. Transcranial vs. transsphenoidal approach in the surgical treatment of pituitary adenomas
41. Non-secretory adenomas of the pituitary treated by trans-ethmoidal sellotomy
42. Management of nonfunctioning pituitary adenomas
43. Recovery of visual and endocrine function following transsphenoidal surgery of large nonfunctioning pituitary adenomas
44. Five-year follow-up of nonsecreting pituitary adenomas
45. Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas
46. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas
47. Nonfunctioning pituitary adenomas: Indications for postoperative radiotherapy
48. Proliferation index of nonfunctioning pituitary adenomas: Correlations with clinical characteristics and long term follow up results
49. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas
50. Postoperative MRI appearance after transsphenoidal pituitary tumor resection
51. The treatment of pituitary chromophobe adenomas
52. Pituitary adenomas
53. Radiotherapy for non-functioning pituitary tumours
54. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - A follow-up study
55. Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase α monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts
56. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence
57. The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas
58. Clinical features and growth fractions of pituitary adenomas
59. Neuro-ophthalmological assessment of vision before and after radiation therapy alone for pituitary macroadenomas
60. Results of surgery and irradiation or irradiation alone for pituitary adenomas
61. Pituitary adenoma: The efficacy of radiotherapy as the sole treatment
62. Long-term follow-up of radiotherapy for pituitary adenoma: The absence of late recurrence after greater than or equal to 4500cGy
63. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas
64. Radiotherapy for nonfunctional pituitary adenoma: Analysis of long-term tumor control
65. Radiotherapy of nonfunctional adenomas of the pituitary gland. Results with long-term follow-up
66. Pituitary adenoma radiotherapy - When, who and how?
67. Radiation therapy for pituitary adenoma: Treatment outcome and prognostic factors
68. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine
69. Size reduction of extrasellar pituitary tumours during bromocriptine treatment. Quantitation of effect on different types of tumours
70. Is there a real medical treatment for 'non secreting' pituitary adenomas?
71. Dopamine agonists and pituitary tumour shrinkage
72. Rapid improvement in visual field defects following bromocriptine treatment of patients with non-functioning pituitary adenomas
73. Rapid improvement in visual defects with parenteral depot bromocriptine in a patient with a nonfunctioning pituitary adenoma
74. Long-term treatment with dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma
75. 123I-methoxybenzamide with hormone levels and tumour size response to quinagolide in patients with pituitary adenomas
76. 123I-methoxybenzamide
77. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: Evidence for different tumours subclasses
78. Clinically non-functioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro
79. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by non-functioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group
80. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy
81. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas
82. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas
83. Gonadotropin releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin secreting pituitary adenomas
84. Effects of long term treatment with the gonadotropin releasing hormone analog nafarelin in patients with non-functioning pituitary adenomas